Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma

Blood

Volumn 93, Issue 8, 1999, Pages 2688-2696

  Ten Berge, Rosita L ^b   Dukers, Danny F ^b   Oudejans, Joost J ^b   Pulford, Karen ^b   Ossenkoppele, Gert J ^b   De Jong, Daphne ^b   Miseré, Jo F M M ^b   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PHOSPHOTRANSFERASE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME INDUCTION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY;

EID: 0033561193     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.8.2688     Document Type: Article

References (52)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HC, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
2. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G: ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91:2076, 1998
3. de Bruin PC, Beljaards RC, van Heerde P, van der Valk P, Noorduyn LA, van Krieken JHJM, Kluin-Nelemans JC, Willemze R, Meijer CJLM: Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 23:127, 1993
4. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJLM: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354, 1997
5. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Brière J: Primary anaplastic large-cell lymhoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 90:3727, 1997
6. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281, 1994
7. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinoshama R, Abe M, Nakano M, Yamamoto T, Mori S: Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 84: 3648, 1994
8. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394, 1997
9. Pittaluga S, Wlodarska I, Pulford K, Campo E, Morris SW, Van den Berghe H, De Wolf-Peeters C: The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 151:343, 1997
10. Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME, Vardiman JW: The t(2;5)(p23; q35): A recurring chromosomal abnormality in Ki-1-positive large cell lymphoma. Leukemia 3:866, 1989
11. Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, LeBeau MM, Stephens JK, Vardiman JW: Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 14:305, 1990
12. Sandlund JT, Pui CH, Roberts M, Santana VM, Morris SW, Berard CW, Hutchison RE, Ribeiro RC, Mahmoud H, Crist WM, Heim M, Raimondi SC: Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84:2467, 1994
13. Shiota M, Nakamura S, Ichinoshama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Mohri N, Nasu K, Satoh H, Katano H, Fujimoto J, Yamamoto T, Mori S: Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954, 1995
14. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Baak JPA, Kluin PM, van der Valk P, Walboomers JMM, Meijer CJLM: Analysis of major histocompatibility complex class I expression in Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus positive and negative Hodgkin's disease. Blood 87:3844, 1996
15. Poppema S, Visser L: Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 145:37, 1994
16. Lee SP, Constandinou CM, Thomas WA, Croomcarter D, Blake NW, Murray PG, Crocker J, Rickinson AB: Antigen presenting phenotype of Hodgkin-Reed-Sternberg cells - analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein Barr Virus-specific cytotoxic T-cell recognition. Blood 92:1020, 1998
17. Taga K, Tosato G: IL-10 inhibits human T-cell proliferation and IL-2 production. J Immunol 148:1143, 1992
18. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R: Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T-cells and downregulates HLA class I expression. J Exp Med 180:2371, 1994
19. Ohshima K, Suzumiya J, Akamatu M, Takeshita M, Kikuchi M: Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int J Cancer 62:5, 1995
20. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PhM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJLM: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 89:1376, 1997
21. Brink AATP, Oudejans JJ, van den Brule AJC, Kluin PhM, Horstman A, Ossenkoppele GJ, van Heerde P, Jiwa NM, Meijer CJLM: Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome of Hodgkin's disease: Involvement of apoptosis resistance. Mod Pathol 11:376, 1998
22. Kummer JA, Kamp AM, van Katwijk M, Brakenhoff JPJ, Radosevic K, van Leeuwen AM, Borst J, Verweij CL, Hack CE: Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods 163:77, 1993
23. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJLM, Hack E: Localization and identification of granzymes A and B expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 100:164, 1995
24. Anderson P, Nagler-Anderson C, O'Brien C, Levine H, Watkins S, Slayter HS, Blue ML, Schlossman SF: A monoclonal antibody reactive with a 15 kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T-lymphocytes. J Immunol 144:574, 1990
25. Anderson P: TIA-1: Structural and functional studies on a new class of cytolytic effector molecule. Curr Top Microbiol Immunol 198:131, 1995
26. Griffiths GM: The cell biology of CTL killing. Curr Opin Immunol 7:343, 1995
27. Podack ER: Execution and suicide: Cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 7:11, 1995
28. Shresta S, MacIvor DM, Heusel JW, Russel JH, Ley TJ: Natural killer and lymphokine activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA 92:5679, 1995
29. Heusel JW, Wesselschmidt RL, Shresta S, Russel JH, Ley TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogenic target cells. Cell 76:977, 1994
30. Bobrow MN, Shaughnessy KJ, Litt GJ: Catalized reporter deposition: A novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods 125:279, 1989
31. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
32. Cox DR: Regression models and life tables. J R Stat Soc Br 34:187, 1972
33. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F: Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514, 1997
34. Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460, 1995
35. Kummer JA, Vermeer MH, Dukers DF, Meijer CJLM, Willemze R: Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 109:636, 1997
36. Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M: Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for a distinct cellular origin. Blood 89:980, 1997
37. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, Hummel M, Stein H: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88:4005, 1996
38. Tu Y, Renner S, Xu FH, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajweski S, Reed JC, Lichtenstein A: Bcl-x expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 58:256, 1998
39. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by bcl-2. Cell 79:329, 1994
40. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650, 1994
41. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell mediated cytotoxicity. Science 265:528, 1994
42. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC: Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/APO-1)-mediated apoptosis. Blood 91:2875, 1998
43. Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78, 1995
44. Freisen C, Herr I, Krammer pH, Debatin K: Involvement of the CD95 (APO1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:574, 1996
45. Yang E, Korsmeyer S: Molecular thanatopsis: A discourse on the bcl2 family and cell death. Blood 88:386, 1996
46. Schröter M, Lowin B, Borner C, Tschopp J: Regulation of Fas (APO-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur J Immunol 25:3509, 1995
47. Nuñez G, Merino R, Grillot D, González-García M: Bcl-2 and bcl-x: Regulatory switches for lymphoid death and survival. Immunol Today 15:582, 1994
48. Messineo C, Hunter Jamerson M, Hunter E, Braziel R, Bagg A, Irving SG, Cossman J: Gene expression by single Reed-Sternberg cells: Pathways of apoptosis and activation. Blood 91:2443, 1998
49. Becker JC, Czerny C, Brocker EB: Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6:1605, 1994
50. Ding L, Shevach EM: IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage co-stimulatory function. J Immunol 148:3133, 1992
51. Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Brière J, Brousse N, Emile JF, Joab I, Kanavaros P, Gaulard P: Interleukin-10 is frequently expressed in anaplastic T-cell lymphomas. Presented at the IX Meeting European Association for Haematopathology. Leiden, The Netherlands, April 26-29, 1998, p 25
52. Sun JR, Bird CH, Sutton V, McDonald L, Coughlin PB, Dejong TA, Trapani JA, Bird PI: A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine respons modifier A is present in cytotoxic lymphocytes. J Biol Chem 271:27802, 1996